about
Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasisClinical and parasitological protection in a Leishmania infantum-macaque model vaccinated with adenovirus and the recombinant A2 antigenVisceral leishmaniasis in the Indian subcontinent: modelling epidemiology and controlVaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c miceNanodisk-associated amphotericin B clears Leishmania major cutaneous infection in susceptible BALB/c miceSodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages.Effect of Amphotericin B Nanodisks on Leishmania major Infected Mice.Detection, differentiation, and quantitation of pathogenic leishmania organisms by a fluorescence resonance energy transfer-based real-time PCR assay.Use of antimony in the treatment of leishmaniasis: current status and future directions.Inhibition of ABC transporters abolishes antimony resistance in Leishmania InfectionThe relationship between leishmaniasis and AIDS: the second 10 yearsOptimizing efficacy of amphotericin B through nanomodification.Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood.Human immunodeficiency virus and leishmaniasis.Drug-resistant microorganisms with a higher fitness--can medicines boost pathogens?Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine.
P2860
Q28343835-C373F972-D415-4885-8C32-76A495F592A7Q28539852-DC49D88F-03F2-46EE-83EC-3E15C01A3E87Q34091527-6B65D752-76FD-49EB-AA86-3FFC95239D51Q34123352-EA93BBD5-423E-48C7-8FF6-301C2A0DCD64Q34510505-A4552BF7-EBF3-4CA6-9981-7F0E3E077891Q34648790-15C6EC94-346A-43C3-926E-7505110A1ACEQ34889020-2FD2196F-75D5-49B1-BE70-536BCBD7EB71Q34975222-8168C651-30CE-413E-8B17-6A3CF34A2722Q35377767-2255E108-B068-4E9D-8F49-2061A4CE2AF9Q36482756-F41C099F-3859-4532-8647-269C40386683Q36538814-EEE43077-3EAE-4BC5-ADE8-C2A5043E44E5Q36920328-141C31E8-0408-417F-A336-76957C8C09C1Q37125732-623AFD69-373B-4A2F-A485-1D27EC997D3BQ37798456-BD263336-E32D-4A70-A5B3-F48EC6B8F7B3Q38040818-6EE3B70D-B9AF-45D0-8F4B-14998BE892B5Q39537428-4B2734E6-AC75-4214-A934-8DBB3508CDE8
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Kala-azar as an AIDS-related opportunistic infection.
@ast
Kala-azar as an AIDS-related opportunistic infection.
@en
type
label
Kala-azar as an AIDS-related opportunistic infection.
@ast
Kala-azar as an AIDS-related opportunistic infection.
@en
prefLabel
Kala-azar as an AIDS-related opportunistic infection.
@ast
Kala-azar as an AIDS-related opportunistic infection.
@en
P356
P1476
Kala-azar as an AIDS-related opportunistic infection.
@en
P2093
P304
P356
10.1089/108729199318183
P577
1999-08-01T00:00:00Z